PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Ark Therapeutics Group PLC

5 Feb 2013 14:48

RNS Number : 1810X
Richard Griffiths
05 February 2013
 



FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Identity of the person whose positions/dealings are being disclosed:

Seren Capital Management

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

Richard Griffiths

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

ARK Therapeutics

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

4/2/13

(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?

 

NO

 

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

2,930,000

1.40

(2) Derivatives (other than options):

(3) Options and agreements to purchase/sell:

TOTAL:

 

2,930,000

1.40

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

Number of securities

Price per unit

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

 None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

5/2/13

Contact name:

Chris Hill

Telephone number:

01481738724

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETLLFFSFEIEIIV
Date   Source Headline
14th Jun 201011:45 amRNSForm 8.5 (EPT/RI)
14th Jun 20109:16 amRNSForm 8.5 (EPT/NON-RI)
11th Jun 20102:06 pmRNSForm 8.3 - Ark Therapeutics Group PLC
11th Jun 201012:46 pmRNSForm 8.3 - Ark Therapeutics Plc
11th Jun 201010:16 amRNSForm 8.5 (EPT/RI)
11th Jun 20109:52 amRNSForm 8.5 (EPT/NON-RI)
10th Jun 201010:17 amRNSForm 8.5 (EPT/NON-RI)
10th Jun 201010:13 amRNSForm 8.5 (EPT/RI)
9th Jun 201011:38 amRNSForm 8.5 (EPT/RI)
9th Jun 201010:08 amRNSForm 8.5 (EPT/NON-RI)
8th Jun 20104:40 pmRNSSecond Price Monitoring Extn
8th Jun 20104:35 pmRNSPrice Monitoring Extension
8th Jun 201012:36 pmRNSForm 8.3 - Ark Therapeutics
8th Jun 201011:15 amRNSForm 8.5 (EPT/NON-RI)
8th Jun 201011:11 amRNSForm 8.5 (EPT/RI)
7th Jun 20102:53 pmRNSForm 8.3 - Ark Therapeutics Group PLC
7th Jun 201011:55 amRNSForm 8.3 - [Ark Therapeutics Group plc]
7th Jun 201011:04 amRNSForm 8.5 (EPT/RI)-Amendment
7th Jun 201011:04 amRNSForm 8.5 (EPT/RI)
7th Jun 20109:41 amRNSForm 8.5 (EPT/NON-RI)
4th Jun 201012:43 pmRNSForm 8.3 - ARK THERAPEUTICS
4th Jun 201011:43 amRNSForm 8.5 (EPT/RI)
4th Jun 201010:25 amRNSForm 8.5 (EPT/NON-RI)
3rd Jun 20102:53 pmRNSForm 8.3 - Ark Therapeutics Group PLC
3rd Jun 201011:37 amRNSForm 8.5 (EPT/RI)
3rd Jun 201011:25 amRNSForm 8.5 (EPT/NON-RI)
3rd Jun 201010:28 amRNSBlocklisting Interim Review
2nd Jun 20103:07 pmRNSForm 8.3 - Ark Therapeutics Group PLC
2nd Jun 201011:38 amRNSForm 8.5 (EPT/RI)
2nd Jun 20109:22 amRNSForm 8.5 (EPT/NON-RI)
1st Jun 20102:47 pmRNSForm 8.3 - Ark Therapeutics Group PLC
1st Jun 20102:45 pmRNSForm 8.3 - Ark Therapeutics
1st Jun 201010:08 amRNSForm 8.5 (EPT/NON-RI)
28th May 201011:08 amRNSForm 8.5 (EPT/NON-RI)
27th May 20103:17 pmRNSForm 8.3 - Ark Therapeutics Group PLC
27th May 201010:41 amRNSForm 8.5 (EPT/RI)
27th May 20109:04 amRNSForm 8.5 (EPT/NON-RI)
26th May 201011:45 amRNSForm 8.5 (EPT/NON-RI)
25th May 20104:40 pmRNSSecond Price Monitoring Extn
25th May 20104:35 pmRNSPrice Monitoring Extension
25th May 201010:44 amRNSForm 8.5 (EPT/NON-RI)
24th May 20109:10 amRNSForm 8.5 (EPT/NON-RI)
24th May 20107:00 amRNSAppointment of CFO and Company Secretary
21st May 20103:32 pmRNSForm 8.5 (EPT/RI)
21st May 20109:55 amRNSForm 8.5 (EPT/NON-RI)
20th May 20109:50 amRNSForm 8.5 (EPT/NON-RI)
19th May 201010:48 amRNSForm 8.5 (EPT/NON-RI)
18th May 201011:05 amRNSForm 8.5 (EPT/NON-RI)
18th May 201010:11 amRNSForm 8.5 (EPT/RI)
18th May 20107:00 amRNSInterim Management Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.